Results 121 to 130 of about 216,339 (397)

Topoisomerase 1 Promoter Variants and Benefit from Irinotecan in Metastatic Colorectal Cancer Patients [PDF]

, 2016
Objective: Topoisomerase 1 (topo-1) is an important target for the treatment of metastatic colorectal cancer (CRC). The aim of the present study was to evaluate the correlation between topo-1 single-nucleotide polymorphisms (SNPs) and clinical outcome in
Crea, F., Danesi, R., De Gregorio, V., Falcone, A., Fornaro, L., Graziano, F., Loupakis, F., Masi, G., Paolicchi, E., Ricci, V., Ronzoni, M., Vivaldi, C.   +11 more
core   +1 more source

Insight into pericytes in glioblastoma angiogenesis: In vivo tracking by two‐photon microscopy and proteomic profiling

Animal Models and Experimental Medicine, EarlyView.
Based on the inducible pericyte ablation model, we discovered that Pdgfrb+ pericytes regulate glioblastoma (GBM) growth. Using the pericyte lineage tracing model, we revealed their dynamic behavior during GBM angiogenesis. Proteomic analysis combined with pericyte RNA analysis based on human single‐cell data demonstrated cross‐species conserved ...
Qinghong Wang, Chengyan Ma, Xinpei Wang, Mengyuan Li, Xingjiu Yang, Ran Gao   +5 more
wiley   +1 more source

Bevacizumab in maintenance therapy for ovarian cancer patients

Южно-Российский онкологический журнал, 2020
Ovarian cancer is one of the most common cancers in women. Growth and extension of the tumor are associated with active neoangiogenesis regulated by vascular endothelial growth factor (VEGF).
L. Yu. Vladimirova, A. E. Storozhakova, E. A. Kalabanova, E. V. Verenikina, S. N. Kabanov, Ya. V. Svetitskaya, N. Yu. Samaneva, N. M. Tikhanovskaya, K. A. Novoselova, O. G. Selezneva, A. V. Tishina   +10 more
doaj   +1 more source

Rindopepimut with Bevacizumab for Patients with Relapsed EGFRvIII-Expressing Glioblastoma (ReACT): Results of a Double-Blind Randomized Phase II Trial

Clinical Cancer Research, 2020
Purpose: Rindopepimut is a vaccine targeting the tumor-specific EGF driver mutation, EGFRvIII. The ReACT study investigated whether the addition of rindopepimut to standard bevacizumab improved outcome for patients with relapsed, EGFRvIII-positive ...
D. Reardon, A. Desjardins, J. Vredenburgh, D. O’Rourke, D. Tran, K. Fink, L. Nabors, Gordon Li, D. Bota, R. Lukas, L. Ashby, J. Duic, M. Mrugala, S. Cruickshank, L. Vitale, Yi He, Jennifer A Green, M. Yellin, C. Turner, T. Keler, T. Davis, J. Sampson, ReACT trial investigators   +22 more
semanticscholar   +1 more source

Immunoscintigraphy for therapy decision making and follow-up of biological therapies [PDF]

, 2016
With the availability of new biological therapies there is the need of more accurate diagnostic tools to noninvasively assess the presence of their targets.
Auletta, S., Carideo, Luciano, Galli, Filippo, Lauri, Chiara, Pacilio, Massimiliano, Signore, Alberto, Valabrega, Stefano   +6 more
core   +2 more sources

Status of oncology drugs with a conditional approval: A cross‐sectional comparison of the Food and Drug Administration and Health Canada

British Journal of Clinical Pharmacology, EarlyView.
Aims This study looks at the status of the same drugs conditionally approved by the Food and Drug Administration and Health Canada for the same oncology indication. Methods Lists of oncology drugs with a conditional approval from the Food and Drug Administration and Health Canada were generated and drug pairs with the same indication were matched ...
Joel Lexchin
wiley   +1 more source

Risk of severe pulmonary embolism in cancer patients receiving bevacizumab: Results from a meta-analysis of published and unpublished data

Tumor Biology, 2017
To evaluate the association between severe pulmonary embolism events and bevacizumab, we conducted the first meta-analysis evaluating the incidence and risk of pulmonary embolism associated with bevacizumab-based therapy.
Meidan Liu, Yayuan Zheng, Zuguang Chen, Yumiao Qiu, Zhanchun Pan, Zitao Cai, Yapeng Shi, Junfen Cheng, Weimin Yao   +8 more
doaj   +1 more source

Bevacizumab Monotherapy or Combined with Laser versus Laser Monotherapy in Mongolian Patients with Diabetic Macular Edema

Central Asian Journal of Medical Sciences, 2016
Objectives: To evaluate the efficacy and safety of bevacizumab monotherapy and bevacizumab therapy combined with laser therapy versus laser monotherapy in Mongolian patients with visual impairment due to diabetic macular edema (DME). Methods: One hundred
Anaraa Toishubai, Uranchimeg Davaatseren, Baasankhuu Jamyanjav, Sun Taek Lim, Bulgan Tuvaan, Munkhzaya Tsengenbayar, Munkhkhishig Batbileg, Oyunzaya Luvsantseren, Urangua Jamyansuren, Munkhsaikhan Munkhkhuyag, Unudeleg Bayaraa, Khudrenchuluun Nanjid, Yerkyebulan Muktar, Unurtsetseg Chandaga, Chimedsuren Ochir   +14 more
doaj   +1 more source

Adaptive immunity in cancer immunology and therapeutics. [PDF]

, 2014
Copyright: © the authors; licensee ecancermedicalscience. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution,
Lockley, M, Spurrell, EL
core   +2 more sources

Availability, use, efficacy and safety of bevacizumab in European hereditary haemorrhagic telangiectasia centres

British Journal of Clinical Pharmacology, EarlyView.
Introduction Bevacizumab, a vascular endothelial growth factor inhibitor, is used off‐label for treatment of severe anaemia related to epistaxis, gastrointestinal bleeding and/or severe hepatic arteriovenous malformations (HAVM) and right‐sided cardiac failure in patients with hereditary haemorrhagic telangiectasia (HHT).
Pernille D. Haahr, Anette D. Kjeldsen, Annette D. Fialla, Anne‐Emmanuelle Fargeton, Alexandre Guilhem, Elisabetta Buscarini, Freya Droege, Guido Manfredi, Hans‐Jurgen Mager, Jean‐Christophe Saurin, Jens Kjeldsen, Josefien Hessels, Marco C. Post, Robert Mandic, Sanne Boerman, Stefan Kasper‐Virchow, Sören Möller, Urban Geisthoff, Sophie Dupuis‐Girod   +18 more
wiley   +1 more source